Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity.
Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity.
复制标题
肠道微生物群衍生的代谢物作为肥胖中关键的黏膜屏障调节剂
DOI：
10.3748/wjg.v27.i33.5555
复制
发表时间：
2021-09-07
影响因子：
4.3
通讯作者：
Wang YG
中科院分区：
文献类型：
--
作者：
Wei YX;Zheng KY;Wang YG
肥胖研究领域的一个重大突破是证明肥胖表型可以通过调节肠道微生物群来操纵。下一步重要的是阐明与人类相关的微生物-宿主相互作用的“地图”，这些相互作用调节宿主的代谢健康。对这种串扰的更好理解是优化治疗策略以对抗肥胖的先决条件。肠粘膜屏障功能障碍是代谢性疾病的重要促成因素，并且还被发现涉及多种其他慢性炎症性病症，包括癌症、神经变性和衰老。肠屏障功能障碍伴随代谢紊乱的机制基础仍然知之甚少。了解肠道屏障功能的分子和细胞调节剂将有助于设计改进的策略，以抵消肠道屏障破坏的有害全身后果。肠道微生物群的组成和功能的变化，即，生态失调被认为是肥胖相关发病机制的驱动因素，并且可能是粘膜屏障功能障碍的最重要驱动因素之一。微生物群对宿主的许多影响是由微生物群衍生的代谢产物介导的。在这篇综述中，我们重点关注几种研究相对充分的微生物代谢物，它们可以影响肠道粘膜动态平衡，并讨论它们如何影响代谢疾病。设计和使用在肠道中具有局部活性而没有全身副作用的微生物及其代谢物是代谢性疾病的有希望的新颖且安全的治疗方式。
A significant breakthrough in the field of obesity research was the demonstration that an obese phenotype could be manipulated by modulating the gut microbiota. An important next step is to elucidate a human-relevant “map’’ of microbiota-host interactions that regulate the metabolic health of the host. An improved understanding of this crosstalk is a prerequisite for optimizing therapeutic strategies to combat obesity. Intestinal mucosal barrier dysfunction is an important contributor to metabolic diseases and has also been found to be involved in a variety of other chronic inflammatory conditions, including cancer, neurodegeneration, and aging. The mechanistic basis for intestinal barrier dysfunction accompanying metabolic disorders remains poorly understood. Understanding the molecular and cellular modulators of intestinal barrier function will help devise improved strategies to counteract the detrimental systemic consequences of gut barrier breakage. Changes in the composition and function of the gut microbiota, i.e., dysbiosis, are thought to drive obesity-related pathogenesis and may be one of the most important drivers of mucosal barrier dysfunction. Many effects of the microbiota on the host are mediated by microbiota-derived metabolites. In this review, we focus on several relatively well-studied microbial metabolites that can influence intestinal mucosal homeostasis and discuss how they might affect metabolic diseases. The design and use of microbes and their metabolites that are locally active in the gut without systemic side effects are promising novel and safe therapeutic modalities for metabolic diseases.
登录
查看更多内容
影响因子：
7.7
作者：
Cani, Patrice D.;Amar, Jacques;Burcelin, Remy
通讯作者：
Burcelin, Remy
影响因子：
64.8
作者：
Chassaing B;Koren O;Goodrich JK;Poole AC;Srinivasan S;Ley RE;Gewirtz AT
通讯作者：
Gewirtz AT
尿石素可减轻高脂肪饮食大鼠的多种肥胖症状。
DOI：
10.2147/dmso.s268146
发表时间：
2020
期刊：
Diabetes, metabolic syndrome and obesity : targets and therapy
影响因子：
--
作者：
Abdulrahman AO;Kuerban A;Alshehri ZA;Abdulaal WH;Khan JA;Khan MI
通讯作者：
Khan MI
DOI：
10.1126/science.aam9949
发表时间：
2017-08-11
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Byndloss MX;Olsan EE;Rivera-Chávez F;Tiffany CR;Cevallos SA;Lokken KL;Torres TP;Byndloss AJ;Faber F;Gao Y;Litvak Y;Lopez CA;Xu G;Napoli E;Giulivi C;Tsolis RM;Revzin A;Lebrilla CB;Bäumler AJ
通讯作者：
Bäumler AJ
影响因子：
29
作者：
Donohoe DR;Garge N;Zhang X;Sun W;O'Connell TM;Bunger MK;Bultman SJ
通讯作者：
Bultman SJ